DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease

Abstract

Background: Vedolizumab (VDZ) is the first gut-specific monoclonal antibody alternative to anti-tumour necrosis factor alpha (anti-TNFalpha) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD). It has been registered since 2016 in Hungary. All newly initiated VDZ therapy was individualised, it should be approved by the steering committee of five Hungarian IBD specialists. Aims of our non-interventional retrospective study to assess the efficacy of induction VDZ therapy on clinical and endoscopic activity in moderate or severe active IBD with previous anti-TNF failure or intolerance in real-life setting. Method(s): Anti-TNF-alpha therapy intolerant IBD patients who received induction VDZ therapy were enrolled between July 2016 and July 2017 in Hungary. The therapeutic response was assessed based on the changes of clinical (Crohn's Disease Activity Index [CDAI], Mayo score) and endoscopic (Simple Endoscopic Score for Crohn Disease [SES-CD], endoscopic Mayo score) scores. Clinical response was defined as >3 points decrease in the total Mayo score or >100 decrease in CDAI score from baseline. Remission was defined as Mayo score 1, or as CDAI score